Learn more about Elsevier’s Drug Patient Education today! Empower and engage your patients to use medication safely.
BAMLANIVIMAB (bam lan iv' i mab) is a monoclonal antibody. It is used with another monoclonal antibody to treat COVID-19 in patients who are not hospitalized. It is also used to reduce the risk of getting COVID-19. It is for patients at risk of getting severe symptoms of COVID-19. It may decrease the risk of developing severe symptoms of COVID-19. It may also decrease the chance of going to the hospital. This medication is not approved by the FDA. The FDA has authorized emergency use of this medication during the COVID-19 pandemic.
This medication is for infusion into a vein. It is given by your care team in a clinic setting.
Talk to your care team regarding the use of this medication in children. While this medication may be prescribed for children as young as newborns for selected conditions, precautions do apply.
Side effects that you should report to your care team as soon as possible:
Side effects that usually do not require medical attention (report these to your care team if they continue or are bothersome):
This medication is given in a clinic and will not be stored at home.
They need to know if you have any of these conditions:
This does not apply.
Your condition will be monitored carefully while you are receiving this medication. Visit your care team for regular checkups. Tell your care team if your symptoms do not start to get better or if they get worse.
After receiving this medication, you will need to wait before getting the COVID-19 vaccine. Talk to your care team about when you can receive the COVID-19 vaccine.
Cookies are used by this site. To decline or learn more, visit our cookies page.